Gregory W. Roloff

729 total citations
28 papers, 453 citations indexed

About

Gregory W. Roloff is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Gregory W. Roloff has authored 28 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 12 papers in Public Health, Environmental and Occupational Health and 9 papers in Genetics. Recurrent topics in Gregory W. Roloff's work include Acute Myeloid Leukemia Research (20 papers), Acute Lymphoblastic Leukemia research (12 papers) and Cancer Genomics and Diagnostics (9 papers). Gregory W. Roloff is often cited by papers focused on Acute Myeloid Leukemia Research (20 papers), Acute Lymphoblastic Leukemia research (12 papers) and Cancer Genomics and Diagnostics (9 papers). Gregory W. Roloff collaborates with scholars based in United States, Australia and India. Gregory W. Roloff's co-authors include Elizabeth A. Griffiths, Lucy A. Godley, Michael W. Drazer, Christopher S. Hourigan, Gen Suzuki, Arsalan Shabbir, David Zisa, Michalis Mastri, Techung Lee and Huey Lin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Gregory W. Roloff

27 papers receiving 448 citations

Peers

Gregory W. Roloff
Gregory W. Roloff
Citations per year, relative to Gregory W. Roloff Gregory W. Roloff (= 1×) peers Michele Gottardi

Countries citing papers authored by Gregory W. Roloff

Since Specialization
Citations

This map shows the geographic impact of Gregory W. Roloff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory W. Roloff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory W. Roloff more than expected).

Fields of papers citing papers by Gregory W. Roloff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory W. Roloff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory W. Roloff. The network helps show where Gregory W. Roloff may publish in the future.

Co-authorship network of co-authors of Gregory W. Roloff

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory W. Roloff. A scholar is included among the top collaborators of Gregory W. Roloff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory W. Roloff. Gregory W. Roloff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roloff, Gregory W., Caner Saygin, Adam DuVall, et al.. (2025). Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. eJHaem. 6(3). e70078–e70078. 1 indexed citations
2.
Roloff, Gregory W., Satyajit Kosuri, Adam DuVall, et al.. (2024). Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 109(11). 3739–3744. 1 indexed citations
3.
Wang, Peng, Madhu P. Menon, Anand Patel, et al.. (2024). Somatic co‐alteration signatures are prognostic in high‐grade TP53‐mutated myeloid neoplasms. British Journal of Haematology. 206(4). 1103–1108. 1 indexed citations
5.
Roloff, Gregory W., et al.. (2023). Clinical guideline variability in the diagnosis of hereditary hematopoietic malignancy syndromes. Leukemia & lymphoma. 64(9). 1562–1565. 3 indexed citations
6.
Roloff, Gregory W., et al.. (2023). Stagnation in quality of next‐generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies. Journal of Genetic Counseling. 32(3). 744–749. 4 indexed citations
7.
O’Connor, Timothy E., et al.. (2023). Clinical considerations at the intersection of hematopoietic cell transplantation and hereditary hematopoietic malignancy. Frontiers in Oncology. 13. 1180439–1180439. 2 indexed citations
8.
Shaw, Reid, Timothy E. O’Connor, Gregory W. Roloff, et al.. (2023). Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplantation. Frontiers in Oncology. 13. 1146002–1146002. 3 indexed citations
9.
Roloff, Gregory W., Rawan Faramand, Ibrahim Aldoss, et al.. (2023). Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.. Journal of Clinical Oncology. 41(16_suppl). 7001–7001. 8 indexed citations
10.
Saygin, Caner, Gregory W. Roloff, Christopher N Hahn, et al.. (2022). Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Advances. 7(4). 549–554. 23 indexed citations
11.
Saygin, Caner, Gregory W. Roloff, Christopher N Hahn, et al.. (2022). Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies. Blood. 140(Supplement 1). 10542–10544. 1 indexed citations
12.
Roloff, Gregory W., Reid Shaw, Timothy E. O’Connor, & Michael W. Drazer. (2022). Stagnation in Quality of Next-Generation Sequencing Assays for the Diagnosis of Hereditary Hematopoietic Malignancies. Blood. 140(Supplement 1). 5090–5091.
13.
Roloff, Gregory W., et al.. (2021). Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports. 16(5). 394–404. 2 indexed citations
14.
Roloff, Gregory W., Lucy A. Godley, & Michael W. Drazer. (2020). Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. Genetics in Medicine. 23(1). 211–214. 17 indexed citations
15.
Wong, Hong Yuen, Anthony D. Sung, Katherine E. Lindblad, et al.. (2019). Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response. Frontiers in Oncology. 8. 669–669. 14 indexed citations
16.
Dillon, Laura W., Sheida Hayati, Gregory W. Roloff, et al.. (2018). Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia. Haematologica. 104(2). 297–304. 30 indexed citations
17.
Griffiths, Elizabeth A., Pragya Srivastava, Junko Matsuzaki, et al.. (2017). NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clinical Cancer Research. 24(5). 1019–1029. 76 indexed citations
18.
Meaburn, Karen J., et al.. (2016). Tissue-of-origin-specific gene repositioning in breast and prostate cancer. Histochemistry and Cell Biology. 145(4). 433–446. 20 indexed citations
19.
Roloff, Gregory W., Zhiming Yang, Lauren V. Wood, & Vladimir Neychev. (2016). Colon cancer metastasis to the thyroid gland: report of a case with unique molecular profile. Clinical Case Reports. 4(6). 549–553. 4 indexed citations
20.
Roloff, Gregory W., et al.. (2015). Locus-specific gene repositioning in prostate cancer. Molecular Biology of the Cell. 27(2). 236–246. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026